Glenmark Pharmaceuticals stock (INE935A01035): Q4 FY26 earnings and share price in focus on NSE India

Glenmark Pharmaceuticals shares on NSE India reflect the market's reaction to the company's Q4 FY26 results and recent growth trends, as investors assess the outlook for the Indian generics and specialty medicines group.

Glenmark Pharmaceuticals shares on the National Stock Exchange of India traded actively after the company presented its Q4 FY26 financial performance, keeping the Mumbai-based drug maker in focus on the domestic equity market as investors weighed the latest numbers against prior growth and profitability trends, according to data from the NSE India quote page as of 06/02/2026 and the company’s Q4 FY26 earnings call transcript.

The stock is listed on NSE India under the ticker GLENMARK and on BSE, giving Glenmark broad visibility in its home market of India, where it competes in the pharmaceuticals and biotechnology segment and is often tracked as part of the wider Indian healthcare universe, as shown on the NSE India profile page.

The company held its Q4 FY26 earnings conference call in late May 2026, during which management discussed quarterly and full-year results, including developments in key geographies such as India, North America and Europe, according to the Q4 FY26 earnings call transcript published by GuruFocus.

While the detailed Q4 FY26 numbers were broken out by business region and product categories during the call, management commentary highlighted ongoing efforts to strengthen branded formulations in India and specialty and generic portfolios in regulated markets, a theme that has been consistent across recent reporting periods per the same transcript.

Investors in India have followed Glenmark’s recent earnings trajectory closely after an earlier quarter in FY26 saw a sharp year-over-year revenue increase, with one analysis on Tickertape noting a 76% revenue jump for Q2 FY26 driven by operational performance and the contribution from core businesses.

External coverage has pointed out that Glenmark’s earnings per share climbed significantly in the past year, with Simply Wall St highlighting a move in EPS from around INR 37.11 to roughly INR 48.26 for the most recent twelve-month period covered in its analysis, indicating solid profitability growth even as quarterly results can fluctuate.

Market commentary around recent quarters has also flagged instances where Glenmark’s reported numbers diverged from some analysts’ expectations; for example, Motilal Oswal noted that a previous quarter delivered revenue broadly in line with its forecasts but EBITDA around 7% below its estimate, illustrating that margin performance remains a key focus area for the sell-side.

For domestic investors on NSE India, the latest Q4 FY26 update and ongoing analyst scrutiny provide context for evaluating Glenmark’s positioning among Indian-listed pharmaceutical peers, especially as the sector continues to balance pricing pressure in generics with opportunities in complex products, specialty drugs and respiratory therapies.

The stock traded at levels that reflected this fundamental backdrop on 06/02/2026 on NSE India, based on the live quote information reported on the official exchange site, although the exact intraday percentage move can vary throughout the trading session as new information and order flow reach the market.

From a home-country perspective, Glenmark’s presence on India’s main equity exchanges and the use of Indian rupees as the trading currency underscore that domestic factors such as Indian healthcare policy, local demand dynamics and rupee movements can influence the share price alongside global pharmaceutical trends.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Glenmark
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Mumbai, India
• Core markets: India, North America, Europe and select international regions
• Key revenue drivers: Branded formulations in India, generic and specialty medicines in regulated markets, and over-the-counter products
• Home exchange/listing venue: NSE India (GLENMARK) and BSE
• Trading currency: INR

Glenmark Pharmaceuticals: core business model

Glenmark Pharmaceuticals focuses on developing and commercializing generics, specialty therapies and over-the-counter medicines across India and key international markets, with sales concentrated in branded formulations at home and complex generic and specialty products abroad.

Latest quarterly results for Glenmark Pharmaceuticals at a glance

Glenmark’s Q4 FY26 performance, as discussed during its earnings call in late May 2026, rounded off a financial year in which management emphasized growth in India formulations and continued traction in regulated markets, alongside ongoing cost discipline and portfolio optimization, according to the Q4 FY26 earnings call transcript hosted by GuruFocus.

During the call, the company outlined how contributions from its core geographies and therapeutic franchises shaped quarterly profitability, while also referencing earlier FY26 quarters in which revenue growth had accelerated, including Q2 FY26 where Tickertape reported a 76% year-over-year increase in revenue on the back of stronger operations, highlighting the volatility across quarters but also Glenmark’s capacity to generate higher top-line growth periods.

Conclusion

Glenmark Pharmaceuticals’ shares on NSE India remain anchored in the company’s Q4 FY26 report and the broader FY26 trajectory, with domestic investors evaluating the balance between periods of strong revenue expansion and quarter-specific margin developments.

The latest quarterly recap and management commentary provide additional context on how Glenmark is positioning its India formulations and international generics and specialty portfolios, which in turn will continue to play a central role in how the market values the stock within the Indian pharmaceutical sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.